Artificial Dermis Market Global Report 2026

The artificial dermis market size has grown strongly in recent years. It will grow from $1.66 billion in 2025 to $1.81 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period was driven by increasing incidence of severe burn injuries, growing number of reconstructive surgical procedures, rising prevalence of chronic wounds, expanding healthcare infrastructure, and improving availability of advanced wound care products.

The artificial dermis market size is expected to see strong growth in the next few years. It will grow to $2.56 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth during the forecast period is driven by growing demand for regenerative medicine solutions, increasing adoption of bioengineered skin substitutes, rising investment in tissue engineering research, expanding access to specialized wound care centers, and increasing focus on improving post-surgical healing outcomes. Major trends during the forecast period include increasing adoption of advanced bioengineered skin substitutes, growing demand for collagen-based dermal regeneration solutions, rising use of composite dermal substitutes in reconstructive surgery, expansion of artificial dermis applications in chronic wound management, and increasing development of next-generation biocompatible dermal scaffolds.

The increasing incidence of burn injuries is expected to drive the growth of the artificial dermis market in the coming years. Burn injuries refer to tissue damage caused by exposure to heat, chemicals, electricity, radiation, or friction, affecting the skin and underlying tissues. The rising occurrence of burn injuries is primarily attributed to the growing frequency of household and industrial accidents, which are often associated with unsafe cooking practices, electrical risks, chemical exposure, and insufficient workplace safety measures. Artificial dermis supports burn injury treatment by acting as a temporary or permanent skin substitute that facilitates wound closure, encourages tissue regeneration, and minimizes scarring and infection risks in patients suffering from extensive skin damage. For example, in October 2023, according to the International Burn Injury Database (iBID), a US-based organization, burns and scalds among children increased by 45% during the first six months of 2023 compared with the same period in 2022, while incidents involving adults and elderly individuals caused by hot water bottles increased by 19%. Therefore, the increasing incidence of burn injuries is driving the growth of the artificial dermis market.

The growing number of trauma and accident cases is expected to drive the growth of the artificial dermis market in the coming years. Trauma and accident cases refer to medical conditions involving injuries caused by sudden external forces, including road traffic collisions, falls, burns, or physical violence, that require immediate medical assessment and treatment. The increasing number of trauma and accident cases is driven by rising road traffic density, which contributes to increased congestion, greater exposure among road users, and a higher probability of accidents. Artificial dermis assists trauma and accident patients by providing a temporary or permanent skin substitute that supports wound closure, lowers infection risks, and accelerates tissue regeneration in severe injuries. For example, in October 2024, according to the Department of Health Alaska, a US-based government department, approximately 3,373 individuals in Alaska experienced traumatic brain injuries (TBI) in 2023. This number includes both fatal cases and non-fatal injuries that received treatment and were discharged from hospitals or emergency departments (ED). Therefore, the growing number of trauma and accident cases is driving the growth of the artificial dermis market.

In April 2023, Essex Bio-Technology Ltd., a China-based biopharmaceutical company that provides collagen-based artificial dermis products, and Gunze Limited entered into a collaboration agreement in mainland China to commercialize PELNAC, a bioresorbable dermal substitute used in advanced wound care applications. Through this partnership, Essex Bio-Technology Ltd. and Gunze Limited aim to enhance the availability and distribution of artificial dermis solutions in China by combining clinical wound care expertise with established regional commercialization capabilities, thereby improving access to regenerative wound healing technologies for surgical and chronic wound management. Gunze Limited is a Japan-based diversified manufacturer involved in textiles, plastics, and medical materials, including advanced wound care products.

Major companies operating in the artificial dermis market are Aroa Biosurgery Limited, AVITA Medical Inc., Elutia Inc., ConvaTec Group plc, Gunze Limited, Integra LifeSciences Holdings Corporation, LifeNet Health Inc., Medline Industries LP, MiMedx Group Inc., Mölnlycke Health Care AB, MTF Biologics, Organogenesis Holdings Inc., Parametrics Medical LLC, PolyNovo Limited, Smith & Nephew plc, Surgenex LLC, Tides Medical LLC, Tissue Regenix Group plc, Vericel Corporation, Vivex Biologics Inc., Zimmer Biomet Holdings Inc.

North America was the dominating region in the artificial dermis market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the artificial dermis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the artificial dermis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.